Literature DB >> 16039578

FcgammaRIV: a novel FcR with distinct IgG subclass specificity.

Falk Nimmerjahn1, Pierre Bruhns, Ken Horiuchi, Jeffrey V Ravetch.   

Abstract

Mouse IgG subclasses display a hierarchy of in vivo activities, with IgG2a and IgG2b showing the greatest protective and pathogenic properties. These enhanced activities result, in part, from their ability to bind to a novel, gamma chain-dependent, activating IgG Fc receptor, FcgammaRIV. FcgammaRIV maps in the 75 kb genomic interval between FcgammaRII and FcgammaRIII; its expression is restricted to myeloid lineage cells, and it binds to IgG2a and IgG2b with intermediate affinity. No binding to IgG1 or IgG3 was observed. Blocking FcgammaRIV binding to pathogenic anti-platelet antibodies is sufficient to protect mice from antibody-induced thrombocytopenia. Thus, the FcgammaR system has evolved distinct activation receptors displaying selectivity for IgG subclasses, with IgG1 antibodies exclusively dependent on FcgammaRIII, whereas IgG2a and IgG2b show preferential dependence on FcgammaRIV activation. These distinct binding affinities for the IgG subclasses to FcgammaRs account for their differential protective and pathogenic activities in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16039578     DOI: 10.1016/j.immuni.2005.05.010

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  247 in total

1.  Requirement of myeloid cell-specific Fas expression for prevention of systemic autoimmunity in mice.

Authors:  Carla M Cuda; Hemant Agrawal; Alexander V Misharin; G Kenneth Haines; Jack Hutcheson; Evan Weber; Joseph A Schoenfeldt; Chandra Mohan; Richard M Pope; Harris Perlman
Journal:  Arthritis Rheum       Date:  2012-03

2.  Stimulation of unprimed macrophages with immune complexes triggers a low output of nitric oxide by calcium-dependent neuronal nitric-oxide synthase.

Authors:  Zhi Huang; Fukun W Hoffmann; Jeffrey D Fay; Ann C Hashimoto; Moti L Chapagain; Pakieli H Kaufusi; Peter R Hoffmann
Journal:  J Biol Chem       Date:  2011-12-28       Impact factor: 5.157

3.  Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement.

Authors:  Fubin Li; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-20       Impact factor: 11.205

Review 4.  The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities.

Authors:  Zhi Huang; Aaron H Rose; Peter R Hoffmann
Journal:  Antioxid Redox Signal       Date:  2012-01-09       Impact factor: 8.401

5.  A Herpes Simplex Virus (HSV)-2 Single-Cycle Candidate Vaccine Deleted in Glycoprotein D Protects Male Mice From Lethal Skin Challenge With Clinical Isolates of HSV-1 and HSV-2.

Authors:  Clare Burn; Natalie Ramsey; Scott J Garforth; Steven Almo; William R Jacobs; Betsy C Herold
Journal:  J Infect Dis       Date:  2018-02-14       Impact factor: 5.226

6.  A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus.

Authors:  Natalie L M Ramsey; Maria Visciano; Richard Hunte; Lip Nam Loh; Clare Burn Aschner; William R Jacobs; Betsy C Herold
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

7.  Macrophages eliminate circulating tumor cells after monoclonal antibody therapy.

Authors:  Nuray Gül; Liane Babes; Kerstin Siegmund; Rianne Korthouwer; Marijn Bögels; Rens Braster; Gestur Vidarsson; Timo L M ten Hagen; Paul Kubes; Marjolein van Egmond
Journal:  J Clin Invest       Date:  2014-01-16       Impact factor: 14.808

Review 8.  Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance.

Authors:  David F Pinelli; Mandy L Ford
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

Review 9.  Regulation of autoreactive B cell responses to endogenous TLR ligands.

Authors:  Ana Maria Avalos; Liliana Busconi; Ann Marshak-Rothstein
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

10.  In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner.

Authors:  Heike Albert; Mattias Collin; Diana Dudziak; Jeffrey V Ravetch; Falk Nimmerjahn
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.